Jennison Associates’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-409,683
| Closed | -$31M | – | 645 |
|
|
2021
Q4 | $31M | Sell |
409,683
-7,297
| -2% | -$553K | 0.02% | 290 |
|
|
2021
Q3 | $46.7M | Buy |
416,980
+141,769
| +52% | +$15.9M | 0.03% | 230 |
|
|
2021
Q2 | $44.6M | Hold |
275,211
| – | – | 0.03% | 239 |
|
|
2021
Q1 | $33.5M | Sell |
275,211
-2,083
| -0.8% | -$254K | 0.02% | 280 |
|
|
2020
Q4 | $42.5M | Sell |
277,294
-2,807
| -1% | -$430K | 0.03% | 230 |
|
|
2020
Q3 | $23.4M | Buy |
280,101
+913
| +0.3% | +$76.4K | 0.02% | 282 |
|
|
2020
Q2 | $20.5M | Buy |
279,188
+102,689
| +58% | +$7.55M | 0.02% | 288 |
|
|
2020
Q1 | $7.49M | Buy |
+176,499
| New | +$7.49M | 0.01% | 361 |
|
|
2018
Q4 | – | Sell |
-540,887
| Closed | -$24M | – | 659 |
|
|
2018
Q3 | $24M | Buy |
+540,887
| New | +$24M | 0.02% | 367 |
|